Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer

HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse. The available data indica...

Full description

Saved in:
Bibliographic Details
Main Authors: Harter, P., Mahner, S., Hilpert, F., Runnebaum, I., Ortmann, O., Mustea, A., Sehouli, J., du Bois, A., Wagner, U.
Format: Artigo
Language:Inglês
Published: Georg Thieme Verlag KG 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3964375/
https://ncbi.nlm.nih.gov/pubmed/24771913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0032-1328320
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items